FEN1 Inhibitor SC13 Reverses the Drug Resistance of MCF-7/ADR Cells
The development of multidrug resistance(MDR)in cancer cells during chemotherapy poses a significant challenge in the clinical treatment of breast cancer.One of the main contributors to drug resistance is the robust DNA damage repair capability of tumor cells.The research had revealed that Flap endonuclease 1(FEN1),a core protein involved in the base excision repair(BER)pathway,was highly expressed in adriamycin-resistant breast cancer cells.Moreover,the study found that the FEN1 inhibitor SC13 significantly enhanced the sensitivity of MCF-7/ADR cells to adriamycin.While the precise mechanism of action was not yet fully understood,it was hypothesized that the enhanced sensitivity of MCF-7/ADR cells may be attributed to the activation of potent antitumor responses mediated by the cGAS-STING-NFκB signaling pathways.
breast cancerFEN1adriamycintumor treatmentchemoresistance
万方数据
维普
